These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 24278166

  • 1. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.
    Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A, Böttcher T, Lukas J, Hübner R, Gölnitz U, Röhle A, Dudesek A, Meyer W, Wittstock M, Mascher H.
    PLoS One; 2013; 8(11):e79732. PubMed ID: 24278166
    [Abstract] [Full Text] [Related]

  • 2. LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population.
    Irún P, Cebolla JJ, López de Frutos L, De Castro-Orós I, Roca-Espiau M, Giraldo P.
    Clin Chem Lab Med; 2020 Apr 28; 58(5):798-809. PubMed ID: 32126008
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
    Vernet Machado Bressan Wilke M, Iop GD, Faqueti L, Lemos da Silva LA, Kubaski F, Poswar FO, Michelin-Tirelli K, Randon D, Borelli WV, Giugliani R, Schwartz IVD.
    Int J Mol Sci; 2024 Mar 01; 25(5):. PubMed ID: 38474117
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy.
    Dubiela P, Szymanska-Rozek P, Hasinski P, Lipinski P, Kleinotiene G, Giersz D, Tylki-Szymanska A.
    Biomolecules; 2024 Jul 12; 14(7):. PubMed ID: 39062556
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expanding the clinical utility of glucosylsphingosine for Gaucher disease.
    Saville JT, McDermott BK, Chin SJ, Fletcher JM, Fuller M.
    J Inherit Metab Dis; 2020 May 12; 43(3):558-563. PubMed ID: 31707742
    [Abstract] [Full Text] [Related]

  • 9. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
    Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F.
    Orphanet J Rare Dis; 2014 Jun 30; 9():95. PubMed ID: 24980507
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.
    Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, van Breemen MJ, Ferraz MJ, Groener JE, Maas M, Wijburg FA, Speijer D, Tylki-Szymanska A, Mistry PK, Boot RG, Aerts JM.
    Blood; 2011 Oct 20; 118(16):e118-27. PubMed ID: 21868580
    [Abstract] [Full Text] [Related]

  • 12. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
    Hamler R, Brignol N, Clark SW, Morrison S, Dungan LB, Chang HH, Khanna R, Frascella M, Valenzano KJ, Benjamin ER, Boyd RE.
    Anal Chem; 2017 Aug 15; 89(16):8288-8295. PubMed ID: 28686011
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.
    Revel-Vilk S, Fuller M, Zimran A.
    Int J Mol Sci; 2020 Sep 28; 21(19):. PubMed ID: 32998334
    [Abstract] [Full Text] [Related]

  • 15. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.
    Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, Sidransky E.
    Mol Genet Metab; 2002 Aug 28; 76(4):262-70. PubMed ID: 12208131
    [Abstract] [Full Text] [Related]

  • 16. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.
    Giuffrida G, Markovic U, Condorelli A, Calafiore V, Nicolosi D, Calagna M, Grasso S, Ragusa MTV, Gentile J, Napolitano M.
    Orphanet J Rare Dis; 2023 Feb 13; 18(1):27. PubMed ID: 36782327
    [Abstract] [Full Text] [Related]

  • 17. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Abramov A, Zimran A, Revel-Vilk S.
    Int J Mol Sci; 2019 Jun 21; 20(12):. PubMed ID: 31234327
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Application of plasma glucosylsphingosine detection in the follow-up of patients with Gaucher disease].
    Zhan X, Zhang HW, Gao XL, Gu XF, Chen LJ, Guo RB.
    Zhonghua Yi Xue Za Zhi; 2020 Nov 03; 100(40):3169-3173. PubMed ID: 33142401
    [Abstract] [Full Text] [Related]

  • 20. Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.
    Gayed MM, Jung SH, Huggins E, Rodriguez-Rassi E, DeArmey S, Kishnani PS, Stiles AR.
    Int J Mol Sci; 2022 Nov 29; 23(23):. PubMed ID: 36499264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.